Skip to main content

Compare Stocks

Date Range: 

 Design TherapeuticsApriaThoma Bravo AdvantageThredUpBioventus
SymbolNASDAQ:DSGNNYSE:APRNYSE:TBANASDAQ:TDUPNYSE:BVS
Price Information
Current Price$22.29$28.18$10.14$18.50$15.91
52 Week RangeBuyBuyN/ABuyBuy
MarketRank™
Overall Score1.31.40.01.61.4
Analysis Score3.32.50.03.42.5
Community Score3.34.50.04.54.5
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.00.00.0
Earnings & Valuation Score0.00.00.00.00.0
Analyst Ratings
Consensus RecommendationBuyBuyN/ABuyBuy
Consensus Price Target$35.33$29.20N/A$20.86$19.50
% Upside from Price Target58.52% upside3.62% upsideN/A12.74% upside22.56% upside
Trade Information
Market Cap$1.24 billion$997.88 million$1.04 billion$1.68 billion$904.09 million
BetaN/AN/AN/AN/AN/A
Average Volume178,354258,9041,431,948785,818238,881
Sales & Book Value
Annual RevenueN/AN/AN/AN/AN/A
Price / SalesN/AN/AN/AN/AN/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book ValueN/AN/AN/AN/AN/A
Price / BookN/AN/AN/AN/AN/A
Profitability
Net IncomeN/AN/AN/AN/AN/A
EPSN/AN/AN/AN/AN/A
Trailing P/E Ratio0.000.000.000.000.00
Forward P/E Ratio
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/AN/A
Current RatioN/AN/AN/AN/AN/A
Quick RatioN/AN/AN/AN/AN/A
Ownership Information
Institutional Ownership PercentageN/AN/AN/AN/AN/A
Insider Ownership PercentageN/AN/AN/AN/AN/A
Miscellaneous
Employees156,120N/A1,862700
Shares Outstanding55.62 million35.21 million102.40 million90.86 million56.83 million
Next Earnings Date8/9/2021 (Estimated)N/AN/A8/11/2021 (Estimated)8/11/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Bioventus (NYSE:BVS) Releases Quarterly  Earnings ResultsBioventus (NYSE:BVS) Releases Quarterly Earnings Results
americanbankingnews.com - May 13 at 1:36 PM
Bioventus Inc. Reports First Quarter Results; Updates Full Year 2021 Financial GuidanceBioventus Inc. Reports First Quarter Results; Updates Full Year 2021 Financial Guidance
finance.yahoo.com - May 12 at 7:42 PM
Bioventus (NYSE:BVS) Issues FY 2021 Earnings GuidanceBioventus (NYSE:BVS) Issues FY 2021 Earnings Guidance
americanbankingnews.com - May 12 at 5:50 PM
Bioventus (NYSE:BVS) Sees Strong Trading VolumeBioventus (NYSE:BVS) Sees Strong Trading Volume
americanbankingnews.com - May 11 at 10:56 AM
Bioventus (NYSE:BVS) Trading Up 9.3%Bioventus (NYSE:BVS) Trading Up 9.3%
americanbankingnews.com - May 10 at 6:16 PM
Bioventus (BVS) Scheduled to Post Earnings on WednesdayBioventus (BVS) Scheduled to Post Earnings on Wednesday
americanbankingnews.com - May 5 at 2:08 AM
Bioventus (NYSE:BVS) Shares Gap Down to $14.40Bioventus (NYSE:BVS) Shares Gap Down to $14.40
americanbankingnews.com - May 3 at 12:04 PM
Bioventus (NYSE:BVS) Trading Up 4.2%Bioventus (NYSE:BVS) Trading Up 4.2%
americanbankingnews.com - April 28 at 12:38 PM
Bioventus Announces First Commercial Shipment of the Bioness(R) Integrated Therapy System (BITS) Balance SystemBioventus Announces First Commercial Shipment of the Bioness(R) Integrated Therapy System (BITS) Balance System
marketwatch.com - April 28 at 10:02 AM
Bioventus Announces First Commercial Shipment of the Bioness® Integrated Therapy System (BITS) Balance SystemBioventus Announces First Commercial Shipment of the Bioness® Integrated Therapy System (BITS) Balance System
finance.yahoo.com - April 27 at 8:44 AM
Bioventus (NYSE:BVS) Price Target Raised to $19.00 at Morgan StanleyBioventus (NYSE:BVS) Price Target Raised to $19.00 at Morgan Stanley
americanbankingnews.com - April 26 at 9:58 AM
Bioventus (NYSE:BVS) Stock Price Down 2.8%Bioventus (NYSE:BVS) Stock Price Down 2.8%
americanbankingnews.com - April 21 at 1:38 PM
Bioventus (NYSE:BVS) Trading 4.9% Higher  After Analyst UpgradeBioventus (NYSE:BVS) Trading 4.9% Higher After Analyst Upgrade
americanbankingnews.com - April 20 at 1:18 PM
Bioventus (NYSE:BVS) Shares Gap Down to $14.77Bioventus (NYSE:BVS) Shares Gap Down to $14.77
americanbankingnews.com - April 19 at 12:02 PM
Morgan Stanley Raises Bioventus (NYSE:BVS) Price Target to $19.00Morgan Stanley Raises Bioventus (NYSE:BVS) Price Target to $19.00
americanbankingnews.com - April 19 at 10:28 AM
Bioventus to Release First Quarter of Fiscal Year 2021 Financial Results on May 12, 2021Bioventus to Release First Quarter of Fiscal Year 2021 Financial Results on May 12, 2021
finance.yahoo.com - April 12 at 8:08 PM
Medtech firm Bioventus acquires California medical device company in deal worth up to $110MMedtech firm Bioventus acquires California medical device company in deal worth up to $110M
wraltechwire.com - March 31 at 12:58 PM
Bioventus makes multimillion-dollar acquisitionBioventus makes multimillion-dollar acquisition
bizjournals.com - March 31 at 12:58 PM
Bioventus Snaps Up Bioness; Street Remains BullishBioventus Snaps Up Bioness; Street Remains Bullish
smarteranalyst.com - March 31 at 7:57 AM
Bioventus Acquires Bioness, Inc.Bioventus Acquires Bioness, Inc.
finance.yahoo.com - March 30 at 8:34 PM
Bioventus rises before hours on Street-beating Q4Bioventus rises before hours on Street-beating Q4
massdevice.com - March 29 at 1:54 PM
Can Bioventus Inc. (NASDAQ:BVS) still be hot this week?Can Bioventus Inc. (NASDAQ:BVS) still be hot this week?
stocksregister.com - March 27 at 5:51 PM
Bioventus’ 4Q Results Outperform Analysts’ ExpectationsBioventus’ 4Q Results Outperform Analysts’ Expectations
finance.yahoo.com - March 26 at 6:47 AM
Bioventus, Inc. Class A to Host Earnings CallBioventus, Inc. Class A to Host Earnings Call
finance.yahoo.com - March 25 at 7:50 PM
Bioventus Inc. Reports Fourth Quarter and Full Year 2020 Financial Results; Introduces Full Year 2021 Financial GuidanceBioventus Inc. Reports Fourth Quarter and Full Year 2020 Financial Results; Introduces Full Year 2021 Financial Guidance
finance.yahoo.com - March 25 at 7:50 PM
DateCompanyBrokerageAction
4/26/2021Design TherapeuticsPiper SandlerInitiated Coverage
4/26/2021Design TherapeuticsThe Goldman Sachs GroupInitiated Coverage
4/26/2021Design TherapeuticsSVB LeerinkInitiated Coverage
3/31/2021ApriaCitigroupBoost Price Target
3/8/2021ApriaUBS GroupInitiated Coverage
3/8/2021ApriaBank of AmericaInitiated Coverage
5/13/2021ThredUpWells Fargo & CompanyBoost Price Target
5/13/2021ThredUpTelsey Advisory GroupBoost Price Target
5/13/2021ThredUpBarclaysBoost Price Target
4/26/2021ThredUpKeyCorpInitiated Coverage
4/26/2021ThredUpMorgan StanleyInitiated Coverage
4/26/2021ThredUpWilliam BlairInitiated Coverage
3/15/2021BioventusJPMorgan Chase & Co.Initiated Coverage
3/15/2021BioventusCanaccord GenuityInitiated Coverage
(Data available from 5/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.